

ESMO PRECEPTORSHIP PROGRAMME

ESMO Preceptorship on Practising Oncology: Dealing with Special Strategies, Patient Populations and Toxicities

Challenges for Practising Oncologists

Lugano, Switzerland
3-4 October 2024

CO-CHAIRS

Christina H. Ruhlmann, Denmark
Radu Vidra, Romania

SPEAKERS

Alberto Jacobo Cunquero, Spain
Alice Indini, Italy
Ana Krivokuca, Serbia
Gabor Liposits, Denmark
Lazar Popovic, Serbia
Hendrik van Halteren, The Netherlands

LEARNING OBJECTIVES

- Provide a state-of-the art overview on evidence-based perioperative strategies in various tumor settings
- Deliver an overview on the management of challenging clinical situations faced by practicing oncologists in daily practice
- Provide a state-of-the art overview on evidence based perioperative strategies

Thursday, 3 October 2024

09:00-09:10	Welcome and introduction General overview of learning objectives	Radu Vidra, RO
09:10-10:50 100'	SESSION 1 Perioperative strategies in various tumour settings – Part I Breast cancer	Co-Chair: Christina H. Ruhlmann, DK
20'	Participant clinical case discussion (2 x 10')	Faculty
20'	Perioperative strategies in breast cancer	TBD
20'	Immunotherapy in neo-adjuvant, adjuvant or both?	Lazar Popovic, RS
20'	MTB in the treatment of breast cancers	Ana Krivokuca, RS
20'	Q&A	All

10:50-11:20	Coffee break	
11:20-13:00 100'	SESSION 2 Perioperative strategies in various tumour settings – Part II Gastrointestinal cancers	Co-Chair: Radu Vidra, RO
20'	Participant clinical case discussion (2 x 10')	Faculty
20'	Gold standard perioperative strategies upper GI cancer: Is there a place for immunotherapy?	Hendrik van Halteren, NL
20'	Gold standard perioperative strategies lower GI cancer: Is there a place for immunotherapy?	Gabor Liposits, DK
20'	The importance of Molecular Tumour Boards (MTB) in defining class of risk and treatment	Radu Vidra, RO
20'	Q&A	All
13:00-14:00	Lunch	
14:00-15:40 100'	SESSION 3 Perioperative strategies in various tumour settings – Part III Lung Cancer	Co-Chair: Sibylle Loibl, DE
20'	Participant clinical case discussion (2 x 10')	Faculty
20'	Perioperative strategies in resectable non-small cell lung cancer	TBD
20'	Immunotherapy for resectable non-small cell lung cancer: Neo-adjuvant, adjuvant or both?	Alberto Jacobo Conquero, ES
20'	MTB in the treatment of lung cancer	TBD
20'	Q&A	All
15:40-16:10	Coffee break	
16:10-17:50 100'	SESSION 4 Perioperative strategies in various tumor settings – Part III Skin cancers	Co-Chair: Hendrik van Halteren, NL
20'	Participant clinical case discussion (2 x 10')	Faculty
20'	Perioperative strategies in melanoma	Christina H. Ruhlmann, DK
20'	Molecular vs Multidisciplinary Tumour Boards in skin cancers	Alberto Jacobo Conquero, ES
20'	Perioperative strategy non melanoma skin cancers: Immunotherapy, radiotherapy, and surgery	Alice Indini, IT
20'	Q&A	All
20:00	Dinner	

Friday, 4 October 2024

09:00-10:40 100'	SESSION 5 Immunotherapy in special situations – Part I	Co-Chair: Alice Indini, IT
20'	Participant clinical case discussion (2 x 10')	Faculty
20'	Genetic counselling for long-term survivors and cancer patient's relatives	Ana Krivokuca, RS
20'	The MDT in fertility preservation	TBD
20'	Immunotherapy in elderly patients: Can we downgrade based on molecular profile?	Gabor Liposits, DK
20'	Q&A	All
10:40 – 11:10 Coffee break		
11:10-12:50 100'	SESSION 6 Immunotherapy in special situations – Part II	Co-Chair: Jaruska Naidoo, IRL
20'	Participant clinical case discussion (2 x 10')	Faculty
20'	Cumulative and late toxicity in immunotherapy	Alice Indini, IT
20'	Management of rare IO toxicities	Christina H. Ruhlmann, DK
20'	Immunotherapy in patients with inflammatory/autoimmune comorbidities or after solid organ transplantation	Hendrik van Halteren, NL
20'	Q&A	All
12:50-12:55 5'	Conclusion and farewell	Radu Vidra, RO
12:55 – 13:55 Lunch		

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and 5' Q&A / panel discussion